Accessibility Menu
An2 Therapeutics logo

An2 Therapeutics(NASDAQ) ANTX

Market Cap$219.25MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2022)-62%
5 YearN/A
1 Year+423%
1 Month+19%
$5.81
+0.35%
+0.02Today
After hours$5.80-$0.01 (-0.17%)
An2 Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 5.812026-08-21
An2 Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-3.01%USD 5.992026-08-14
1 month+18.81%USD 4.892026-07-22
3 month+19.79%USD 4.852026-05-22
Year to date+409.65%USD 1.142025-12-31
1 year+423.42%USD 1.112025-08-21
3 year-58.29%USD 13.932023-08-22
Since inception-62.27%USD 15.402022-03-25

An2 Therapeutics Financials at a Glance

Market Cap

$219.25MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$36.28M

EPS (TTM)

-$1.07

P/E Ratio

-5.41

Dividend

$0.00

Beta (Volatility)

0.84 (Low)

Price

$5.81

Volume

225,449.996

Open

$5.84

Previous Close

$5.81

Daily Range

$5.50 - $5.89

52-Week Range

$1.00 - $7.19

Estimated Earnings Date

Nov 5, 2026

ANTX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About An2 Therapeutics

AN2 Therapeutics, Inc. makes pills for rare and serious infections. These medicines help patients manage lung diseases and blood cancers. They help people who currently need hospital stays or blood draws.

Medicines in Development

  • Epetraborole for PV: Oral treatment for polycythemia vera, a blood cancer involving excess red blood cells.
  • Epetraborole for NTM: Antibiotic for chronic lung infections that often resist standard drug treatments.
  • AN2-502998: Investigative pill for Chagas disease, a parasite infection that causes heart damage.
  • Boron Chemistry Platform: Research system used to discover new drugs for cancer and bone diseases.

Strategic Moves and Partnerships

  • Announced plans in March 2026 to test epetraborole in a Phase 2 study for blood cancer.
  • Licensed technology from the University of Georgia Research Foundation in October 2023 for Chagas disease treatments.
  • Partnered with Anacor in November 2019 to gain worldwide rights for boron-based drug compounds.
  • Selected a new drug candidate for solid tumors in early 2026.

What Makes the Science Unique?

The company uses a boron chemistry platform to create drugs that traditional methods cannot reach. This approach allows for easy-to-take pills that target diseases with high efficiency and fewer side effects.

Capital and Performance

  • Net loss was $18.2 million for the six months ended June 30, 2026, up 6% year over year.
  • Cash, cash equivalents, and investments totaled $79.9 million as of June 30, 2026.
  • Research and development expenses reached $12.8 million for the six months ended June 30, 2026, up 17% year over year.
  • Private placement proceeds of $37.2 million were raised in March 2026 to support clinical trials.

Bottom Line

AN2 Therapeutics is transitioning from early research to clinical testing using its specialized boron chemistry platform. The company focuses on serious diseases with limited treatment options, positioning its pipeline to address significant unmet medical needs.

AI Generated • Aug 12, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

21

CEO

Eric Easom, MBA

Website

www.an2therapeutics.com

Headquarters

Menlo Park, CA 94025, US

ANTX Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-53.52%

Return on Capital

-71.82%

Return on Assets

-44.41%

Earnings Yield

-18.48%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$219.25MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

37.74M

Volume

225.45K

Avg. Volume

295.31K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$38.81M

EBITDA

-$37.57M

Operating Cash Flow

-$30.68M

Capital Expenditure

$0.00

Free Cash Flow

-$30.68M

Cash & ST Invst.

$78.39M

Total Debt

$0.00

An2 Therapeutics Performance Analysis

An2 Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
An2 Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Q22026-06-30N/A
An2 Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -2.2047.0%
20232023-12-31USD -2.7424.4%
20242024-12-31USD -1.72-37.3%
20252025-12-31USD -1.16-32.3%
An2 Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-47.6%
Q42025-12-316.5%
Q12026-03-31N/A
Q22026-06-3037.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$219.25MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$10.44M

N/A

Employees

21

N/A

Net Income

-$8.19M

-26.7%

EBITDA

-$8.19M

-26.7%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$78.39M

+24.6%

Total Debt

$0.00

N/A

Accounts Receivable

$300.00K

-88.9%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-44.41%

N/A

Return on Invested Capital

-51.01%

N/A

Free Cash Flow

-$7.00M

+7.9%

Operating Cash Flow

-$7.00M

+7.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SABSSAB Biotherapeutics, Inc.
$3.78+2.16%
VRCAVerrica Pharmaceuticals Inc.
$4.82-0.82%
BOLDBoundless Bio, Inc.
$3.00+3.45%
NXTCNextCure, Inc.
$6.29+0.64%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.77+0.10%
IBITiShares Bitcoin Trust
$43.68+0.06%
BITOProShares Trust - ProShares Bitcoin ETF
$10.41+0.06%
MARAMara Holdings
$11.26+0.01%

Questions About ANTX

What is the current price of An2 Therapeutics?

An2 Therapeutics is trading at $5.81 per share.

What is the 52-week range for An2 Therapeutics?

Over the past 52 weeks, An2 Therapeutics has traded between $1.00 and $7.19.

How much debt does An2 Therapeutics have?

As of the most recent reporting period, An2 Therapeutics reported total debt of $0.00.

How much cash does An2 Therapeutics have on hand?

An2 Therapeutics reported $44.32M in cash and cash equivalents in its most recent financial results.

What is An2 Therapeutics’s dividend yield?

An2 Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services